GSK TB 014 Project – A Phase II, Double Blind (Observer-Blind), Randomised, Controlled Study To Evaluate The Safety, Reactogenicity And Immunogenicity of GSK Biologicals’ Candidate Tuberculosis Vaccine (M72/As01e) When Administered Intramuscularly According To A 0,1 Month Schedule To HIV-Positive Adults Living In A TB Endemic Region